Your browser doesn't support javascript.
loading
Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
Park, Jihye; Cheon, Jae Hee; Lee, Kang-Moon; Kim, Young-Ho; Ye, Byong Duk; Eun, Chang Soo; Kim, Sung Hyun; Lee, Sun Hee; Lee, Joon Ho; Schreiber, Stefan.
Affiliation
  • Park J; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Cheon JH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Lee KM; Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • Kim YH; Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Ye BD; Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Eun CS; Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.
  • Kim SH; Medical Science Division, Celltrion, Inc., Incheon, Korea.
  • Lee SH; Medical Science Division, Celltrion, Inc., Incheon, Korea.
  • Lee JH; Medical Science Division, Celltrion, Inc., Incheon, Korea.
  • Schreiber S; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
Gut Liver ; 17(3): 430-440, 2023 05 15.
Article in En | MEDLINE | ID: mdl-35975641
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Crohn Disease / Biosimilar Pharmaceuticals Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Gut Liver Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Crohn Disease / Biosimilar Pharmaceuticals Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Gut Liver Year: 2023 Document type: Article